WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H123553
CAS#: 2417408-46-7
Description: YX-2-107 is a PROTAC targeting CDK2/4/6.
Hodoodo Cat#: H123553
Name: YX-2-107
CAS#: 2417408-46-7
Chemical Formula: C45H51N11O9
Exact Mass: 889.39
Molecular Weight: 889.970
Elemental Analysis: C, 60.73; H, 5.78; N, 17.31; O, 16.18
Synonym: YX-2-107; SCHEMBL24172331; HY-148530; CS-0634381
IUPAC/Chemical Name: N-(4-((2-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-2-oxoethyl)amino)butyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
InChi Key: JNYCZFGLJGFFEL-UHFFFAOYSA-N
InChi Code: InChI=1S/C45H51N11O9/c1-26-31-23-49-45(52-40(31)55(28-8-3-4-9-28)43(63)38(26)27(2)57)50-34-14-12-29(22-48-34)53-18-20-54(21-19-53)37(60)24-46-16-5-6-17-47-36(59)25-65-33-11-7-10-30-39(33)44(64)56(42(30)62)32-13-15-35(58)51-41(32)61/h7,10-12,14,22-23,28,32,46H,3-6,8-9,13,15-21,24-25H2,1-2H3,(H,47,59)(H,51,58,61)(H,48,49,50,52)
SMILES Code: O=C1NC(C(CC1)N2C(C3=C(C2=O)C(OCC(NCCCCNCC(N4CCN(CC4)C5=CN=C(NC6=NC(N(C7CCCC7)C(C(C(C)=O)=C8C)=O)=C8C=N6)C=C5)=O)=O)=CC=C3)=O)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 889.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Porazzi P, De Dominici M, Salvino J, Calabretta B. Targeting the CDK6
Dependence of Ph+ Acute Lymphoblastic Leukemia. Genes (Basel). 2021 Aug
29;12(9):1355. doi: 10.3390/genes12091355. PMID: 34573335; PMCID: PMC8467343.
2: De Dominici M, Porazzi P, Xiao Y, Chao A, Tang HY, Kumar G, Fortina P,
Spinelli O, Rambaldi A, Peterson LF, Petruk S, Barletta C, Mazo A, Cingolani G,
Salvino JM, Calabretta B. Selective inhibition of Ph-positive ALL cell growth
through kinase-dependent and -independent effects by CDK6-specific PROTACs.
Blood. 2020 Apr 30;135(18):1560-1573. doi: 10.1182/blood.2019003604. PMID:
32040545; PMCID: PMC7193186.